@article{636a35c933de416a8a09f7ad3bad1f6e,
title = "The gut microbiome is a significant risk factor for future chronic lung disease",
abstract = "Background: The gut-lung axis is generally recognized, but there are few large studies of the gut microbiome and incident respiratory disease in adults. Objective: We sought to investigate the association and predictive capacity of the gut microbiome for incident asthma and chronic obstructive pulmonary disease (COPD). Methods: Shallow metagenomic sequencing was performed for stool samples from a prospective, population-based cohort (FINRISK02; N = 7115 adults) with linked national administrative health register–derived classifications for incident asthma and COPD up to 15 years after baseline. Generalized linear models and Cox regressions were used to assess associations of microbial taxa and diversity with disease occurrence. Predictive models were constructed using machine learning with extreme gradient boosting. Models considered taxa abundances individually and in combination with other risk factors, including sex, age, body mass index, and smoking status. Results: A total of 695 and 392 statistically significant associations were found between baseline taxonomic groups and incident asthma and COPD, respectively. Gradient boosting decision trees of baseline gut microbiome abundance predicted incident asthma and COPD in the validation data sets with mean area under the curves of 0.608 and 0.780, respectively. Cox analysis showed that the baseline gut microbiome achieved higher predictive performance than individual conventional risk factors, with C-indices of 0.623 for asthma and 0.817 for COPD. The integration of the gut microbiome and conventional risk factors further improved prediction capacities. Conclusions: The gut microbiome is a significant risk factor for incident asthma and incident COPD and is largely independent of conventional risk factors.",
keywords = "asthma, COPD, Gut, metagenomics, microbiome",
author = "Yang Liu and Teo, {Shu Mei} and Guillaume M{\'e}ric and Tang, {Howard H.F.} and Qiyun Zhu and Sanders, {Jon G.} and Yoshiki V{\'a}zquez-Baeza and Karin Verspoor and Vartiainen, {Ville A.} and Pekka Jousilahti and Leo Lahti and Teemu Niiranen and Havulinna, {Aki S.} and Rob Knight and Veikko Salomaa and Michael Inouye",
note = "Funding Information: V.S. was supported by the Finnish Foundation for Cardiovascular Research and by Juho Vainio Foundation . M.I. was supported by the Munz Chair of Cardiovascular Prediction and Prevention. A.S.H. was supported by the Academy of Finland (grant no. 321356). L.L. was supported by the Academy of Finland (grant nos. 295741 and 328791). T.N. was supported by the Emil Aaltonen Foundation , the Finnish Foundation for Cardiovascular Research , the Sigrid Jus{\'e}lius Foundation, and the Academy of Finland (grant no. 321351). This study was supported by the Victorian government{\textquoteright}s Operational Infrastructure Support program and by core funding from the British Heart Foundation (grant nos. RG/13/13/30194 and RG/18/13/33946) and the NIHR Cambridge Biomedical Research Centre (grant no. BRC-1215-20014). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council , the Engineering and Physical Sciences Research Council , the Economic and Social Research Council , the Department of Health and Social Care (England), the Chief Scientist Office of the Scottish Government Health and Social Care Directorates, the Health and Social Care Research and Development Division ( Welsh Government ), the Public Health Agency (Northern Ireland), the British Heart Foundation , and Wellcome. Funding Information: V.S. was supported by the Finnish Foundation for Cardiovascular Research and by Juho Vainio Foundation. M.I. was supported by the Munz Chair of Cardiovascular Prediction and Prevention. A.S.H. was supported by the Academy of Finland (grant no. 321356). L.L. was supported by the Academy of Finland (grant nos. 295741 and 328791). T.N. was supported by the Emil Aaltonen Foundation, the Finnish Foundation for Cardiovascular Research, the Sigrid Jus{\'e}lius Foundation, and the Academy of Finland (grant no. 321351). This study was supported by the Victorian government's Operational Infrastructure Support program and by core funding from the British Heart Foundation (grant nos. RG/13/13/30194 and RG/18/13/33946) and the NIHR Cambridge Biomedical Research Centre (grant no. BRC-1215-20014). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, the Engineering and Physical Sciences Research Council, the Economic and Social Research Council, the Department of Health and Social Care (England), the Chief Scientist Office of the Scottish Government Health and Social Care Directorates, the Health and Social Care Research and Development Division (Welsh Government), the Public Health Agency (Northern Ireland), the British Heart Foundation, and Wellcome. Publisher Copyright: {\textcopyright} 2023 The Authors",
year = "2023",
doi = "10.1016/j.jaci.2022.12.810",
language = "English (US)",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
}